ReoPro
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background: Saphenous vein graft (SVG) percutaneous coronary intervention (PCI) carries a high risk of ischemic complications…
Abciximab (Reopro®) is an antibody fragment that dose-dependently inhibits platelet aggregation and leucocyte adhesion by binding…
Inhibitors of the platelet receptor glycoprotein (GP) IIb–IIIa are a novel and potent class of antithrombotic drugs for the…
Summary Abciximab (c7E3 Fab, ReoPro®) blocks GPIIb/IIIa and αvβ3 and inhibits thrombotic and proliferative events only in humans…
In the treatment of atherosclerotic disease, stenting in the presence of a glycoprotein (GP) IIb/IIIa antagonist is becoming an…
Orgaran, a heparinoid, has been used successfully in patients with heparin‐induced thrombocytopenia. We report three cases in…
We report a complication observed in a 77-year-old man admitted to another hospital for "de novo" angina, in which coronary…
Abstract Effects on hyperacute rejection were studied in a discordant model with the platelet GPIIb/IIIa antagonist Reopro. Pig…
The platelet membrane glycoprotein (GP) IIb/IIIa integrin receptor is the final common pathway leading to platelet aggregation…